StockData
Gossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS) stock

GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 1/30
$10.72−0.51 (-4.54%)

Close on Nov 20, 2026Market cap $5.24BP/E –Yield –

Gossamer Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Gossamer Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$162.63M. For fiscal 2025 it was -$171.35M. The highest annual figure on record is -$3.47M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$171.35M–
FY2024Dec 31, 2024-$3.47M–
FY2023Dec 31, 2023-$159.16M–
FY2022Dec 31, 2022-$187.44M–
FY2021Dec 31, 2021-$190.44M–
FY2020Dec 31, 2020-$177.86M–
FY2019Dec 31, 2019-$147.80M–
FY2018Dec 31, 2018-$54.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$39.42M–
Q1 FY2026Mar 31, 2026-$38.72M–
Q4 FY2025Dec 31, 2025-$48.31M–
Q3 FY2025Sep 30, 2025-$36.17M–
Q2 FY2025Jun 30, 2025-$47.11M-140.5%
Q1 FY2025Mar 31, 2025-$39.75M–
Q4 FY2024Dec 31, 2024-$35.48M–
Q3 FY2024Sep 30, 2024-$32.03M–
Q2 FY2024Jun 30, 2024$116.35M–
Q1 FY2024Mar 31, 2024-$52.30M–
Q4 FY2023Dec 31, 2023-$33.42M–
Q3 FY2023Sep 30, 2023-$34.49M–
Q2 FY2023Jun 30, 2023-$38.25M–
Q1 FY2023Mar 31, 2023-$52.99M–
Q4 FY2022Dec 31, 2022-$47.83M–
Q3 FY2022Sep 30, 2022-$37.03M–
Q2 FY2022Jun 30, 2022-$48.94M–
Q1 FY2022Mar 31, 2022-$53.64M–
Q4 FY2021Dec 31, 2021-$40.59M–
Q3 FY2021Sep 30, 2021-$42.56M–
Q2 FY2021Jun 30, 2021-$47.59M–
Q1 FY2021Mar 31, 2021-$59.70M–
Q4 FY2020Dec 31, 2020-$36.99M–
Q3 FY2020Sep 30, 2020-$45.23M–
Q2 FY2020Jun 30, 2020-$42.84M–
Q1 FY2020Mar 31, 2020-$52.81M–
Q4 FY2019Dec 31, 2019-$44.67M–
Q3 FY2019Sep 30, 2019-$36.82M–
Q2 FY2019Jun 30, 2019-$38.19M–
Q1 FY2019Mar 31, 2019-$28.12M–
Q4 FY2018Dec 31, 2018-$25.35M–
Q3 FY2018Sep 30, 2018-$17.23M–
Q2 FY2018Jun 30, 2018-$7.74M–
Q1 FY2018Mar 31, 2018-$4.22M–

More Gossamer Bio figures

See a number that looks wrong?